Rescue of functional CFTR channels in cystic fibrosis: A dramatic multivalent effect using iminosugar cluster-based correctors

ChemBioChem

Volumn 14, Issue 15, 2013, Pages 2050-2058

  Compain, Philippe ^a,b   Decroocq, Camille ^a   Joosten, Antoine ^a   de Sousa, Julien ^a   Rodríguez Lucena, David ^a,e   Butters, Terry D ^c   Bertrand, Johanna ^d   Clément, Romain ^d   Boinot, Clément ^d   Becq, Frédéric ^d   Norez, Caroline ^d  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITÉ DE POITIERS   (France)

^e INSTITUTO DE INVESTIGACIONES QUÍMICAS   (Spain)

Author keywords

CFTR correctors; Cystic fibrosis; Iminosugars; Multivalency; Protein folding diseases

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IMINOSUGAR; MIGLUSTAT;

ARTICLE; CELL PROLIFERATION; CLICK CHEMISTRY; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTEIN FOLDING;

CFTR CORRECTORS; CYSTIC FIBROSIS; IMINOSUGARS; MULTIVALENCY; PROTEIN FOLDING DISEASES;

CELL MEMBRANE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DESIGN; HL-60 CELLS; HUMANS; IMINO SUGARS; MUTATION;

EID: 84885422576     PISSN: 14394227     EISSN: 14397633     Source Type: Journal    
DOI: 10.1002/cbic.201300312     Document Type: Article

References (47)

1. M. E. Hodson, Respiration 2000, 67, 595-607.
2. B. J. Rosenstein, G. R. Cutting, J. Pediatr. 1998, 132, 589-595.
3. A. Hamosh, S. C. Fitz-Simmons, M. Macek, Jr., M. R. Knowles, B. J. Rosenstein, G. R. Cutting, J. Pediatr. 1998, 132, 255-259.
4. P. M. Farrell, J. Cystic Fibrosis 2008, 7, 450-453.
5. J. A. Tabcharani, X. B. Chang, J. R. Riordan, J. W. Hanrahan, Nature 1991, 352, 628-631.
6. D. C. Gadsby, A. C. Nairn, Physiol. Rev. 1999, 79, S77-S107.
7. N. Kartner, O. Augustinas, T. J. Jensen, A. L. Naismith, J. R. Riordan, Nat. Genet. 1992, 1, 321-327.
8. S. Pind, J. R. Riordan, D. B. Williams, J. Biol. Chem. 1994, 269, 12784-12788.
9. S. H. Cheng, R. J. Gregory, J. Marshall, S. Paul, D. W. Souza, G. A. White, C. R. O'Riordan, A. E. Smith, Cell 1990, 63, 827-834.
10. F. Becq, M. A. Mall, D. N. Sheppard, M. Conese, O. Zegarra-Moran, J. Cystic Fibrosis 2011, 10, S129-S145;
11. V. Birault, R. Solari, J. Hanrahan, D. Y. Thomas, Curr. Opin. Chem. Biol. 2013, 17, 353-360.
12. C. Norez, S. Noel, M. Wilke, M. Bijvelds, H. Jorna, P. Melin, H. DeJonge, F. Becq, FEBS Lett. 2006, 580, 2081-2086.
13. S. Noel, C. Faveau, C. Norez, C. Rogier, Y. Mettey, F. Becq, J. Pharmacol. Exp. Ther. 2006, 319, 349-359.
14. C. Norez, F. Antigny, S. Noel, C. Vandebrouck, F. Becq, Am. J. Respir. Cell Mol. Biol. 2009, 41, 217-225.
15. T. M. Cox, R. H. Lachmann, C. Hollak, J. M. F. G. Aerts, S. van Weely, M. Hrebicek, F. M. Platt, T. D. Butters, R. A. Dwek, C. Moyses, I. Gow, D. Elstein, A. Zimran, Lancet 2000, 355, 1481-1485.
16. D. Elstein, C. Hollak, J. M. F. G. Aerts, S. van Weely, M. Maas, T. M. Cox, R. H. Lachmann, M. Hrebicek, F. M. Platt, T. D. Butters, R. A. Dwek, A. Zimran, J. Inherited Metab. Dis. 2004, 27, 757-766.
17. A. Leonard, P. Lebecque, J. Dingemanse, T. Leal, J. Cystic Fibrosis 2012, 11, 231-236.
18. Iminosugars: From Synthesis to Therapeutic Applications (Eds.: P. Compain, O. R. Martin), Wiley, Chichester, 2007.
19. D. Best, S. F. Jenkinson, A. W. Saville, D. S. Alonzi, M. R. Wormald, T. D. Butters, C. Norez, F. Becq, Y. Blériot, I. Adachi, A. Kato, G. W. J. Fleet, Tetrahedron Lett. 2010, 51, 4170-4174.
20. N. Ardes-Guisot, D. S. Alonzi, G. Reinkensmeier, T. D. Butters, C. Norez, F. Becq, S. Nakagawa, A. Kato, Y. Blériot, M. Sollogoub, B. Vauzeilles, Org. Biomol. Chem. 2011, 9, 5373-5388.
21. F. P. Da Cruz, S. Newberry, S. F. Jenkinson, M. R. Wormald, T. D. Butters, D. S. Alonzi, S. Nakagawa, F. Becq, C. Norez, R. J. Nash, A. Kato, G. W. J. Fleet, Tetrahedron Lett. 2011, 52, 219-223.
22. J. M. F. G. Aerts, R. G. Boot (Academisch Medisch Centrum), WO 2007123403 A1, 2007.
23. P. Compain, C. Decroocq, J. Iehl, M. Holler, D. Hazelard, T. Mena Barragán, C. Ortiz Mellet, J.-F. Nierengarten, Angew. Chem. 2010, 122, 5889-5892; Angew. Chem. Int. Ed. 2010, 49, 5753-5756.
24. C. Decroocq, D. Rodríguez-Lucena, V. Russo, T. Mena Barragán, C. Ortiz Mellet, P. Compain, Chem. Eur. J. 2011, 17, 13825-13831.
25. C. Decroocq, D. Rodríguez-Lucena, K. Ikeda, N. Asano, P. Compain, ChemBioChem 2012, 13, 661-664.
26. S. Molinski, P. D. W. Eckford, S. Pasyk, S. Ahmadi, S. Chin, C. E. Bear, Front. Pharmacol. 2012, 3, 160.
27. N. Pedemonte, G. L. Lukacs, K. Du, E. Caci, O. Zegarra-Moran, L. J. V. Galietta, A. S. Verkman, J. Clin. Invest. 2005, 115, 2564.
28. V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, Angew. Chem. 2002, 114, 2708-2711; Angew. Chem. Int. Ed. 2002, 41, 2596-2599.
29. C. W. Tornøe, M. Christensen, M. J. Meldal, J. Org. Chem. 2002, 67, 3057-3064.
30. I. Papp, J. Dernedde, S. Enders, R. Haag, Chem. Commun. 2008, 5851-5853.
31. A. Mollard, I. Zharov, Inorg. Chem. 2006, 45, 10172-10179.
32. C. Norez, G. D. Heda, T. Jensen, I. Kogan, L. K. Hughes, C. Auzanneau, R. Dérand, L. Bulteau-Pignoux, C. Li, M. Ramjeesingh, H. Li, D. N. Sheppard, C. E. Bear, J. R. Riordan, F. Becq, J. Cystic Fibrosis 2004, 3, 119-121.
33. P. L. McCormack, K. L. Goa, Drugs 2003, 63, 2427-2434.
34. D. S. Alonzi, D. C. Neville, R. H. Lachmann, R. A. Dwek, T. D. Butters, Biochem. J. 2008, 409, 571-580.
35. These data could reflect the lack of ER access by multivalent iminosugars 13b and 10b. However, in an unpublished study performed in our groups on Gaucher disease, these two compounds were found to be better pharmacological chaperones of Asn370Ser β-glucocerebrosidase than 5b, demonstrating their ability to access the ER (see the Supporting Information). For a review on pharmacological chaperones, see J.-Q. Fan, Biol. Chem. 2008, 389, 1-11.
36. C. Norez, F. Bilan, A. Kitzis, Y. Mettey, F. Becq, J. Pharmacol. Exp. Ther. 2008, 325, 89-99.
37. W. Fuller, A. W. Cuthbert, J. Biol. Chem. 2000, 275, 37462-37468.
38. H. Coe, K. Bedard, J. Groenendyk, J. Jung, M. Michalak, Cell Stress Chaperones 2008, 13, 497-507.
39. The fact that 1 is a strong inhibitor of ER α-glucosidase I is a major concern regarding long-term treatments, as this enzyme is involved in the elaboration of the glycan structure of glycoproteins.
40. H. M. Sampson, H. Lam, P.-C. Chen, D. Zhang, C. Mottillo, M. Mirza, K. Qasim, A. Shrier, S.-L. Shyng, J. W. Hanrahan, D. Y. Thomas, Orphanet J. Rare Dis. 2013, 8, 11.
41. For reviews concerning therapeutic approaches to protein folding diseases, see
42. T. K. Chaudhuri, S. Paul, FEBS J. 2006, 273, 1331-1349;
43. F. E. Cohen, J. W. Kelly, Nature 2003, 426, 905-909;
44. L. K. Gavrin, R. A. Denny, E. Saiah, J. Med. Chem. 2012, 55, 10823-10843;
45. C. M. Gomes, Curr. Top. Med. Chem. 2012, 12, 2460-2469.
46. W. Kammouni, B. Moreau, F. Becq, A. Saleh, A. Pavirani, C. Figarella, M. D. Merten, Am. J. Respir. Cell Mol. Biol. 1999, 20, 684-691.
47. F. Bilan, M. Nacfer, F. Fresquet, C. Norez, P. Melin, A. Martin-Berge, M. A. Costa de Beauregard, F. Becq, A. Kitzis, V. Thoreau, Exp. Cell Res. 2008, 314, 2199-2211.